Skip to main content

Table 1 Clinical characteristics of the fracture cohort and non-fracture cohorts

From: Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario

Clinical Characteristics

Fracture cohort

n (%)

Non-fracture cohort

n (%)

Total number of patients

101,773

101,773

Sex

 Female

74,557 (73.3%)

74,557 (73.3%)

 Male

27,216 (26.7%)

27,216 (26.7%)

Age

 Mean ± SDa

80.25 ± 8.37*

80.33 ± 8.75*

 Median (IQR)a

81 (73–87)

81 (73–87)

 66–70 years

16,672 (16.4%)

16,672 (16.4%)

 71–75 years

15,996 (15.7%)

15,996 (15.7%)

 76–80 years

17,952 (17.6%)

17,952 (17.6%)

 81–85 years

20,584 (20.2%)

20,584 (20.2%)

 ≥86 years

30,569 (30.0%)

30,569 (30.0%)

Urban Residence

89,696 (88.1%)

89,696 (88.1%)

Respiratory conditionsb

 Asthma

13,113 (12.9%)

13,113 (12.9%)

 COPD

25,991 (25.5%)

25,991 (25.5%)

Inflammatory conditionsb

 Rheumatoid arthritis

2208 (2.2%)

2208 (2.2%)

 Psoriasis

4985 (4.9%)

4985 (4.9%)

 Spondyloarthritis

2432 (2.4%)

2432 (2.4%)

Cancerb

5166 (5.1%)

5166 (5.1%)

Chronic kidney diseaseb

8909 (8.8%)

8909 (8.8%)

Diabetesb

29,074 (28.6%)

29,074 (28.6%)

Vascular eventsb

 Myocardial infarction

4549 (4.5%)

4549 (4.5%)

 Stroke or cerebrovascular events

28,015 (27.5%)

28,015 (27.5%)

Osteoarthritisb

77,526 (76.2%)

77,526 (76.2%)

Dementiab

18,359 (18.0%)

18,359 (18.0%)

Osteoporosis treatment type within 1 year priora,c

 Any treatment

28,974 (28.5%)**

21,179 (20.8%)**

 Denosumab

1383 (1.4%)**

1088 (1.1%)**

 Bisphosphonate

25,626 (25.2%)**

17,720 (17.4%)**

 Raloxifene

599 (0.6%)**

465 (0.5%)**

 HRT

3259 (3.2%)

3312 (3.3%)

Index fracture by sitea,d

 Hip

26,963 (26.5%)

–

 Wrist

16,467 (16.2%)

–

 Humerus

11,756 (11.6%)

–

 Ribs

10,247 (10.1%)

–

 Tibia/fibula/knee

9859 (9.7%)

–

 Pelvis

7209 (7.1%)

–

 Vertebral

6595 (6.5%)

–

 Radius/ulna

4377 (4.3%)

–

 Multisite

3299 (3.2%)

–

 Femur

2618 (2.6%)

–

 Clavicle/sternum

2383 (2.3%)

 

 Any site

101,773 (100%)

 

Second fracture by sitea,d

 Hip

4956 (4.9%)

–

 Wrist

2002 (2.0%)

–

 Humerus

1814 (1.8%)

–

 Pelvis

1722 (1.7%)

–

 Ribs

1647 (1.6%)

–

 Vertebral

1590 (1.6%)

–

 Multisite

1326 (1.3%)

–

 Tibia/fibula/knee

1164 (1.1%)

–

 Radius/ulna

650 (0.6%)

–

 Femur

620 (0.6%)

–

 Clavicle/sternum

467 (0.5%)

 

 Any site

17,958 (17.6%)

 
  1. Values reported as n (%) unless otherwise indicated; percent of total respective cohort
  2. *p < 0.05, **p < 0.001 statistical significance between fracture cohort and non-fracture cohort
  3. aVariable not used for matching
  4. bTime frame for cancer was 5 years within index data and for all other comorbidities any time prior to index date
  5. cWithin 1 year of index date. Bisphosphonates include alendronate, cyclical etidronate, risedronate, or zoledronic acid. Denosumab is not publicly covered in men and teriparatide in men or women in Ontario
  6. dIndex fragility fracture cases from January 1, 2011 to March 31, 2015. Second fragility fracture cases from the date of index event to March 31, 2017. Reported from highest to lowest number